The recent Medical-Tech-SaaS IPO had some problems in their S-1 report. I expect it to sink to "below ipo level" as the problems could show up in 1-2 quaters after IPO.
The problem is called "Medicity buyout" and hiding the price of acquision besides the main datasheet in S-1.
Second problem is that it has very slow growth.
The problem is called "Medicity buyout" and hiding the price of acquision besides the main datasheet in S-1.
Second problem is that it has very slow growth.
注释
-10%交易结束：到达目标
now 32
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。